CliffBio
small molecule

DESCOVY

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

Loss of exclusivityFebruary 2033latest FDA-listed patent expiry
CompanyGilead Sciences →View the full company profile on CliffBio

Drug detail

Brand nameDESCOVY
Active ingredientEMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
Strength120MG;EQ 15MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2022
Marketing statusRX

Listed patents

PatentExpiresType
8754065*PEDFebruary 2033—
9296769*PEDFebruary 2033—
8754065August 2032substance, product
9296769August 2032substance, product

Regulatory exclusivity

CodeExpires
ODE-457January 2029
M-316June 2028

More from Gilead Sciences

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DESCOVY patent cliff — loss of exclusivity February 2033 | CliffBio